Nov 13 (Reuters)- D.Western Therapeutics Institute Inc CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended 9 months ended Year to Sep 30, 2025 Sep 30, 2024 Dec 31, 2025 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 297 mln 348 mln 400 mln (-14.9 pct) (+11.1 pct) (-15.2 pct) Operating loss 478 mln loss 647 mln loss 670 mln Recurring loss 491 mln loss 665 mln loss 680 mln Net loss 492 mln loss 727 mln loss 680 mln EPS loss 10.75 yen loss 21.61 yen loss 15.88 yen Ann Div NIL NIL -Q2 div NIL NIL -Q4 div NIL NIL NOTE - D.Western Therapeutics Institute Inc. To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4576.T
TABLE-DWTI - 9-MTH group results
Earlier from D.western Therapeutics Institute
- D Western Therapeutics Institute: Q2 FY12/25 Financial Results Briefing Materials
- D Western Therapeutics Institute: FY12/24 Financial Results Briefing Materials
- D Western Therapeutics Institute: Q2 FY12/24 Financial Results Briefing Materials
- D Western Therapeutics Institute: Summary of Consolidated Financial Results for the Six Months Ended June 30, 2023(Based on Japanese GAAP)
